This proprietary scientific approach was originally discovered by Stanford University researchers and exclusively licensed to Aldea. With its ALDH platform, ALDEA has the unique opportunity to pursue novel targets across multiple therapeutics areas to address significant unmet medical needs.
Acute alcohol toxicity
Fanconi anemia
Alcohol metabolism deficiency (ALMD) and it's long term consequences
Other diseases and conditions associated with toxic aldehydes